

**CUPRIC CHLORIDE- cupric chloride injection**  
**Somerset Therapeutics, LLC**

-----  
**Cupric Chloride Injection, USP**  
**FOR I.V. USE ONLY AFTER DILUTION**  
**Plastic Vial**  
**Rx only**

**DESCRIPTION**

Cupric chloride injection, USP 0.4 mg/ mL is a sterile, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 1.07 mg cupric chloride, dihydrate and 9 mg sodium chloride.

The solution contains no bacteriostat, antimicrobial agent or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium hydroxide for pH adjustment. The osmolarity is 0.327 mOsmol/mL (calc.).

Cupric Chloride, USP is chemically designated cupric chloride, dihydrate ( $\text{CuCl}_2 \cdot 2 \text{H}_2\text{O}$ ), a crystalline compound freely soluble in water.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.

The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration.

**CLINICAL PHARMACOLOGY**

Copper is an essential nutrient which serves as a cofactor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Copper also helps maintain normal rates of red and white blood cell formation.

Providing copper during TPN helps prevent development of the following deficiency symptoms: Leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferrin formation, secondary iron deficiency and osteoporosis.

Normal serum copper values range from 80 to 163 mcg/dl (mean, approximately 110 mcg/dl). The serum copper level at which deficiency symptoms appear is not precisely defined. A serum value of 9 mcg copper/dl was reported for one TPN patient who received no copper. The daily turnover of copper through ceruloplasmin is approximately 0.5 mg. Excretion of copper is through the bile (80%), directly through the intestinal wall (16%) and in urine (4%).

**INDICATIONS AND USAGE**

Cupric chloride injection 0.4 mg/mL is indicated for use as a supplement to intravenous

solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

## **CONTRAINDICATIONS**

None known.

## **WARNINGS**

Direct intramuscular or intravenous injection of Cupric chloride injection 0.4 mg/mL is contraindicated, as the acidic pH of the solution (2) may cause considerable tissue irritation.

Liver and/or biliary tract dysfunction may require omission or reduction of copper and manganese doses because these elements are primarily eliminated in the bile.

**WARNING:** This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

## **PRECAUTIONS**

### **General**

Do not use unless the solution is clear and the seal is intact.

Administration of zinc in the absence of copper may cause a decrease in serum copper levels.

Cupric chloride injection 0.4 mg/mL should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed.

It is not recommended to administer copper to a patient with Wilson's Disease, a genetic disease of copper metabolism.

### **Drug Interactions**

Cupric ion may degrade ascorbic acid in total parenteral nutrition (TPN) solutions. In order to avoid this loss of ascorbate, multivitamin additives should be added to TPN solutions immediately prior to infusion. Alternatively, the multivitamin additive may be added to one container of TPN solution, followed by copper in a subsequent container.

### **Laboratory Tests**

Twice monthly serum assays for copper and/or ceruloplasmin are suggested for monitoring copper concentrations in long-term TPN patients. As ceruloplasmin is a cuproenzyme, ceruloplasmin assays may be depressed secondary to copper deficiency.

### **Carcinogenesis, Mutagenesis, and Impairment of Fertility**

Long-term animal studies to evaluate the carcinogenic potential of cupric chloride injection 0.4 mg/mL have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.

### **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cupric chloride injection 0.4 mg/mL is administered to a nursing woman.

### **Pediatric Use**

(See **DOSAGE AND ADMINISTRATION** section.) There are limited data in infants weighing less than 1500 grams.

### **Pregnancy**

Animal reproduction studies have not been conducted with cupric chloride. It is also not known whether cupric chloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Cupric chloride should be given to a pregnant woman only if clearly indicated.

### **Geriatric Use**

An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## **ADVERSE REACTIONS**

None known.

## **DRUG ABUSE AND DEPENDENCE**

None known.

## **OVERDOSAGE**

Copper toxicity can produce prostration, behavior change, diarrhea, progressive marasmus, hypotonia, photophobia and peripheral edema. Such symptoms have been reported with a serum copper level of 286 mcg/dl. Copper toxicity can also result in hemolysis and liver toxicity, including hepatic necrosis which may be fatal. D-penicillamine has been reported effective as an antidote.

## DOSAGE AND ADMINISTRATION

Cupric Chloride Injection, USP 0.4 mg/mL contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See **PRECAUTIONS**.)

## HOW SUPPLIED

Cupric Chloride Injection, USP 0.4 mg/ mL is available in packages as follows:

NDC	Strength	Packaged
70069- 506 -25	4 mg/10 mL (0.4 mg/mL)	25 vials of 10 mL

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

## SPL UNCLASSIFIED

### Manufactured for:

Somerset Therapeutics, LLC.

Somerset, NJ 08873

Made in India

Code No.: KR/DRUGS/KTK/28/289/97

Revised: March, 2024

1200847

ST-CPC/P/00

## PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container Label

NDC 70069-506-01

Rx only

Cupric Chloride Injection, USP

4 mg/10 mL (0.4 mg/mL)

FOR INTRAVENOUS USE ONLY AFTER DILUTION.

NDC 70069-506-01 Rx only

# Cupric Chloride Injection, USP

**4 mg/10 mL**

(0.4 mg/mL)

FOR INTRAVENOUS USE ONLY AFTER DILUTION.

10 mL Single-Dose Vial

Each mL contains cupric chloride, dihydrate 1.07 mg; sodium chloride 9 mg. 0.327 mOsmol/mL (calc.). Usual dosage: See insert. Contains no more than 3,400 mcg/L of aluminum. Discard unused portion.

**Manufactured for:**  
Somerset Therapeutics, LLC.  
Somerset, NJ 08873

**Made in India**  
Code No.:KR/DRUGS/KTK/28/289/97



Keep area blank and varnish free for overprinting LOT and EXP  
7.5 x24mm

Carton Label


NDC 70069-506-25

Rx only

Cupric Chloride Injection, USP

4 mg/10 mL (0.4 mg/mL)

FOR INTRAVENOUS USE ONLY AFTER DILUTION.



## CUPRIC CHLORIDE

cupric chloride injection

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:70069-506
<b>Route of Administration</b>	INTRAVENOUS		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
CUPRIC CHLORIDE (UNII: S2QG841560) (CUPRIC CATION - UNII:8CBV67279L)	CUPRIC CATION	0.4 mg in 1 mL

**Inactive Ingredients**

Ingredient Name	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X)	9 mg in 1 mL
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
WATER (UNII: 059QF0KOOR)	

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70069-506-25	25 in 1 CARTON	05/14/2024	
1	NDC:70069-506-01	10 mL in 1 VIAL, PLASTIC; Type 0: Not a Combination Product		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA216113	05/14/2024	

**Labeler** - Somerset Therapeutics, LLC (079947873)**Registrant** - Somerset Therapeutics, LLC (079947873)**Establishment**

Name	Address	ID/FEI	Business Operations
Somerset Therapeutics Limited		677236695	ANALYSIS(70069-506) , LABEL(70069-506) , PACK(70069-506) , MANUFACTURE(70069-506)

Revised: 5/2024

Somerset Therapeutics, LLC